EGFR and gastric cancer: Randomized phase III trials evaluating the interest of adding EGFR-targeted agents (cetuximab in the EXPAND trial [30] and panitumumab in the REAL3 [31] and MEGA [32] trials) in combination with CT failed to demonstrate any benefits in patients with metastatic and advanced gastric cancer.